ELTX: Elicio Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 53.05
Enterprise Value ($M) 46.87
Book Value ($M) -18.99
Book Value / Share -1.76
Price / Book -2.79
NCAV ($M) -26.73
NCAV / Share -2.48
Price / NCAV -1.98

Profitability (mra)
Return on Invested Capital (ROIC) -6.63
Return on Assets (ROA) -1.51
Return on Equity (ROE) -3.53

Liquidity (mrq)
Quick Ratio 3.40
Current Ratio 3.40

Balance Sheet (mrq) ($M)
Current Assets 30.65
Assets 38.39
Liabilities 57.37
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
08-14 13D/A Gkcc, Llc 38.70 159.90
04-10 13D/A Clal Biotechnology Industries Ltd. 4.68 -19.60

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-25 5,372 20,820 25.80
2024-11-22 5,580 27,185 20.53
2024-11-21 2,934 23,960 12.25
2024-11-20 2,457 34,282 7.17

(click for more detail)

Similar Companies
DYAI – Dyadic International, Inc. EDSA – Edesa Biotech, Inc.
ELDN – Eledon Pharmaceuticals, Inc. ELUT – Elutia Inc.
ENLV – Enlivex Therapeutics Ltd.


Financial data and stock pages provided by
Fintel.io